Cisapride: What can we learn from the rise and fall of a prokinetic?

Journal of Digestive Diseases

Volumn 12, Issue 3, 2011, Pages 147-156

  Quigley, Eamonn Mm ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cisapride; Gastroesophageal reflux; Gastrointestinal motility; Gastroparesis; Prokinetic; Serotonin

Indexed keywords

AMIODARONE; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; DISOPYRAMIDE; ERYTHROMYCIN; FLUCONAZOLE; HYDROXYITRACONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MIBEFRADIL; MICONAZOLE; NEFAZODONE; PHENOTHIAZINE DERIVATIVE; PROCAINAMIDE; PROKINETIC AGENT; QUINIDINE; RITONAVIR; SEROTONIN RECEPTOR; SOTALOL; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROLEANDOMYCIN;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HUMAN; MOTOR PERFORMANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; STOMACH PARESIS; SUDDEN DEATH; TACHYCARDIA; TORSADE DES POINTES;

CISAPRIDE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HUMANS; SEROTONIN AGENTS;

EID: 79957611296     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00491.x     Document Type: Article

References (113)

1. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652-81.
2. Zhou H, Herron J, Clyde C, Lee P, Mechlinski W, Pesco-Koplowitz L. Pharmacokinetic profile of cisapride 20mg after once- and twice-daily dosing. Clin Ther 1998; 20: 292-8.
3. Yamamoto T, Takano K, Sanaka M etal. Pharmacokinetic characteristics of cisapride in elderly patients. Int J Clin Pharmacol Ther 1998; 36: 432-4.
4. Gladziwa U, Bares R, Klotz U etal. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin Pharmacol Ther 1991; 50: 673-81.
5. Meuldermans W, Van Peer A, Hendrickx J etal. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16: 403-9.
6. Desta Z, Soukhova N, Mahal SK, Flockhart DA. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28: 789-800.
7. Bohets H, Lavrijsen K, Hendrickx J etal. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol 2000; 129: 1655-67.
8. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10.
9. Kivistö KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66: 448-53.
10. Chen SD, Kao CH, Chang CS, Chen GH. Salivary function in patients with reflux esophagitis: effect of cisapride. J Nucl Med 1998; 39: 1449-52.
11. Orr WC, Chen CL, Sloan S. The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2001; 15: 1385-8.
12. Smout AJ, Bogaard JW, Grade AC, ten Thije OJ, Akkermans LM, Wittebol P. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985; 26: 246-51.
13. Wallin L, Kruse-Andersen S, Madsen T, Boesby S. Effect of cisapride on the gastro-oesophageal function in normal human subjects. Digestion 1987; 37: 160-5.
14. Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 631-5.
15. Gilbert RJ, Dodds WJ, Kahrilas PJ, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331-6.
16. Cucchiara S, Staiano A, Boccieri A etal. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990; 31: 21-5.
17. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600-5.
18. Paterson WG, Wang H, Beck IT. The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH study. Am J Gastroenterol 1997; 92: 226-30.
19. Horowitz M, Maddox A, Harding PE etal. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92: 1899-907.
20. Inauen W, Emde C, Weber B etal. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025-31.
21. Katschinski M, Schirra J, Arnold R. The efficacy of a 40-mg extended-release formulation of cisapride in the treatment of patients with gastro-oesophageal reflux. Aliment Pharmacol Ther 2000; 14: 113-22.
22. Pouderoux P, Kahrilas PJ. A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 661-6.
23. Gardner JD, Rodriguez-Stanley S, Robinson M, Miner PB Jr. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1819-29.
24. Holloway RH, Downton J, Mitchell B, Dent J. Effect of cisapride on postprandial gastro-oesophageal reflux. Gut 1989; 30: 1187-93.
25. Finizia C, Lundell L, Cange L, Ruth M. The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2002; 14: 9-14.
26. Smythe A, Bird NC, Troy GP, Ackroyd R, Johnson AG. Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro-oesophageal reflux in patients with Barretts' oesophagus? Eur J Gastroenterol 2003; 15: 305-12.
27. Pehlivanov N, Sarosiek I, Whitman R, Olyaee M, McCallum R. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 743-7.
28. Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998; 12: 761-6.
29. Manes G, Domínguez-Muñoz JE, Leodolter A, Malfertheiner P. Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans. Dig Liver Dis 2001; 3: 407-13.
30. Borovicka J, Lehmann R, Kunz P etal. Evaluation of gastric emptying and motility in diabetic gastroparesis with magnetic resonance imaging: effects of cisapride. Am J Gastroenterol 1999; 94: 2866-73.
31. Lazzaroni M, Sangaletti O, Bianchi Porro G. Effect of cisapride on gastric emptying and ileal transit time of balanced liquid meal in healthy subjects. Digestion 1987; 37: 110-3.
32. Jones KL, Horowitz M, Carney BI, Sun WM, Chatterton BE. Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness. Gut 1996; 38: 310-5.
33. Fraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis - effects of cisapride. Gut 1994; 35: 172-8.
34. Stacher G, Granser GV, Bergmann H, Kugi A, Stacher-Janotta G, Höbart J. Slow gastric emptying induced by high fat content of meal accelerated by cisapride administered rectally. Dig Dis Sci 1991; 36: 1259-65.
35. Jian R, Ducrot F, Piedeloup C, Mary JY, Najean Y, Bernier JJ. Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut 1985; 26: 352-8.
36. Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96: 704-12.
37. Feldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171-4.
38. Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987; 28: 300-5.
39. Kawagishi T, Nishizawa Y, Okuno Y, Sekiya K, Morii H. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy. Am J Gastroenterol 1993; 88: 933-8.
40. Richards RD, Valenzuela GA, Davenport KG, Fisher KL, McCallum RW. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38: 811-6.
41. Abell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, Malagelada JR. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616-20.
42. Corinaldesi R, Stanghellini V, Tosetti C etal. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429-32.
43. Stacher G, Bergmann H, Wiesnagrotzki S etal. Intravenous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa. Gastroenterology 1987; 92: 1000-6.
44. Heyland DK, Tougas G, Cook DJ, Guyatt GH. Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. A randomized, double-blind trial. Am J Respir Crit Care Med 1996; 154: 1678-83.
45. Maddern GJ, Jamieson GG, Myers JC, Collins PJ. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Gut 1991; 32: 470-4.
46. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, Mena I, Martin S, Hyman PE. Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind, crossover, placebo-controlled trial. Gastroenterology 1991; 101: 1564-70.
47. Stacher G, Schernthaner G, Francesconi M etal. Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial. J Clin Endocrinol Metab 1999; 84: 2357-62.
48. McClure RJ, Kristensen JH, Grauaug A. Randomised controlled trial of cisapride in preterm infants. Arch Dis Child Fetal Neonatal Ed 1999; 80: F174-7.
49. Verhagen MA, Roelofs JM, Edelbroek MA, Smout AJ, Akkermans LM. The effect of cisapride on duodenal acid exposure in the proximal duodenum in healthy subjects. Aliment Pharmacol Ther 1999; 13: 621-30.
50. Rezende-Filho J, Di Lorenzo C, Dooley CP, Valenzuela JE. Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia. Dig Dis Sci 1989; 34: 1057-62.
51. Testoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A. Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990; 31: 286-90.
52. Vaezi MF, Sears R, Richter JE. Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Dig Dis Sci 1996; 41: 754-63.
53. Chen JD, Ke MY, Lin XM, Wang Z, Zhang M. Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. Aliment Pharmacol Ther 2000; 14: 1041-7.
54. Besherdas K, Leahy A, Mason I, Harbord M, Epstein O. The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1998; 12: 755-9.
55. Stacher G, Steinringer H, Schneider C, Winklehner S, Mittelbach G, Gaupmann G. Effects of cisapride on jejunal motor activity in fasting healthy humans. Gastroenterology 1986; 90: 1210-6.
56. Stacher G, Gaupmann G, Mittelbach G, Schneider C, Steinringer H, Langer B. Effects of oral cisapride on interdigestive jejunal motor activity, psychomotor function, and side-effect profile in healthy man. Dig Dis Sci 1987; 32: 1223-30.
57. Coremans G, Janssens J, Vantrappen G, Chaussade S, Ceccatelli P. Cisapride stimulates propulsive motility patterns in human jejunum. Dig Dis Sci 1988; 33: 1512-9.
58. Evans PR, Bak YT, Kellow JE. Effects of oral cisapride on small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 837-44.
59. Noor N, Small PK, Loudon MA, Hau C, Campbell FC. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998; 33: 605-11.
60. Camilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986; 91: 619-26.
61. Krevsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA, Fisher RS. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 1: 293-304.
62. Krevsky B, Maurer AH, Malmud LS, Fisher RS. Cisapride accelerates colonic transit in constipated patients with colonic inertia. Am J Gastroenterol 1989; 84: 882-7.
63. Bak YT, Kim JH, Lee CH. Cisapride in chronic idiopathic constipation: clinical response and effect on colonic transit time. Korean J Intern Med 1996; 11: 151-6.
64. Jost WH, Schimrigk K. The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease. Wien Klin Wochenschr 1994; 106: 673-6.
65. Geders JM, Gaing A, Bauman WA, Korsten MA. The effect of cisapride on segmental colonic transit time in patients with spinal cord injury. Am J Gastroenterol 1995; 90: 285-9.
66. Roberts JP, Benson MJ, Rogers J, Deeks JJ, Wingate DL, Williams NS. Effect of cisapride on distal colonic motility in the early postoperative period following left colonic anastomosis. Dis Colon Rectum 1995; 38: 139-45.
67. Marzio L, DiGiammarco AM, Capone F etal. Effect of cisapride on human fasting gallbladder volume: a real-time ultrasonographic study. Eur J Clin Pharmacol 1986; 29: 631-3.
68. Takaoka M, Kubota Y, Fujimura K etal. Effect of single and multiple administrations of cisapride on postprandial gallbladder emptying in healthy humans. Intern Med 1994; 33: 381-6.
69. Baldi F, Bianchi Porro G, Dobrilla G etal. Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial. J Clin Gastroenterol 1988; 10: 614-8.
70. Galmiche JP, Fraitag B, Filoche B etal. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35: 649-55.
71. Arvanitakis C, Nikopoułos A, Theoharidis A etal. Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease - a comparative randomized double-blind trial. Aliment Pharmacol Ther 1993; 7: 635-41.
72. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993; 7: 409-15.
73. Schütze K, Bigard MA, Van Waes L, Hinojosa J, Bedogni G, Hentschel E. Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 497-503.
74. Castell DO, Sigmund C Jr, Patterson D etal. Cisapride 20mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998; 93: 547-52.
75. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol 1995; 90: 423-30.
76. Castell D, Silvers D, Littlejohn T etal. Cisapride 20mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group. Aliment Pharmacol Ther 1999; 13: 787-94.
77. Toussaint J, Gossuin A, Deruyttere M, Hublé F, Devis G. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991; 32: 1280-5.
78. Hatlebakk JG, Hyggen A, Madsen PH etal. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319: 550-3.
79. McDougall NI, Watson RG, Collins JS, McFarland RJ, Love AH. Maintenance therapy with cisapride after healing of erosive oesophagitis: a double-blind placebo-controlled trial. Aliment Pharmacol Ther 1997; 11: 487-95.
80. Hatlebakk JG, Johnsson F, Vilien M, Carling L, Wetterhus S, Thøgersen T. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand J Gastroenterol 1997; 32: 1100-6.
81. Vigneri S, Termini R, Leandro G etal. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
82. Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2000; (3): CD002300.
83. Dalby-Payne JR, Morris AM, Craig JC. Meta-analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastroesophageal reflux in children. J Gastroenterol Hepatol 2003; 18: 196-202.
84. Augood C, Gilbert R, Logan S, MacLennan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2002; (3): CD002300.
85. Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2003; (4): CD002300.
86. Jian R, Ducrot F, Ruskone A etal. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657-64.
87. Champion MC, MacCannell KL, Thomson AB etal. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol 1997; 11: 127-34.
88. de Groot GH, de Both PS. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. Aliment Pharmacol Ther 1997; 11: 193-9.
89. Holtmann G, Gschossmann J, Karaus M etal. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999; 13: 1459-65.
90. Havelund T, Oster-Jørgensen E, Eshøj O, Larsen ML, Lauritsen K. Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus. A double-blind controlled trial. Acta Med Scand 1987; 222: 339-43.
91. Camilleri M, Balm RK, Zinsmeister AR. Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. Gastroenterology 1994; 106: 916-23.
92. Camilleri M, Balm RK, Zinsmeister AR. Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility. Aliment Pharmacol Ther 1996; 10: 403-9.
93. Premji SS, Wilson J, Paes B, Gray S. Cisapride: a review of the evidence supporting its use in premature infants with feeding intolerance. Neonatal Netw 1997; 16: 17-21.
94. Enriquez A, Bolisetty S, Patole S, Garvey PA, Campbell PJ. Randomised controlled trial of cisapride in feed intolerance in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 79: F110-3.
95. Benson MJ, Roberts JP, Wingate DL etal. Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride. Gastroenterology 1994; 106: 924-36.
96. Lander A, Redkar R, Nicholls G etal. Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed 1997; 77: F119-22.
97. Müller-Lissner SA. Treatment of chronic constipation with cisapride and placebo. Gut 1987; 28: 1033-8.
98. Nurko S, Garcia-Aranda JA, Worona LB, Zlochisty O. Cisapride for the treatment of constipation in children: a double-blind study. J Pediatr 2000; 136: 35-40.
99. Wager E, Tooley PJ, Pearce GL, Wilton LV, Mann RD. A comparison of two cohort studies evaluating the safety of cisapride: prescription-event monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52: 87-94.
100. Walker AM, Szneke P, Weatherby LB etal. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-62.
101. Levy J, Hayes C, Kern J etal. Does cisapride influence cardiac rhythm? Results of a USA multicenter, double-blind, placebo-controlled pediatric study. J Pediatr Gastroenterol Nutr 2001; 32: 458-63.
102. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748-9.
103. Smalley W, Shatin D, Wysowski DK etal. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284: 3036-9.
104. Gross AS, Goh YD, Addison RS, Shenfield GM. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999; 65: 395-401.
105. Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534-8.
106. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-10.
107. Hancox JC, James AF. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel. Mol Pharmacol 2008; 73: 1592-5.
108. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108: 1027-33.
109. Chhina S, Peverini RL, Deming DD, Hopper AO, Hashmi A, Vyhmeister NRQ. QTc interval in infants receiving cisapride. J Perinatol 2002; 22: 144-8.
110. Tréluyer JM, Rey E, Sonnier M, Pons G, Cresteil T. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 2001; 52: 419-25.
111. Cools F, Benatar A, Bruneel E etal. A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. Eur J Clin Pharmacol 2003; 59: 17-22.
112. Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607-9.
113. Quigley EMM. The clinical pharmacology of motility disorders: the perils (and pearls) of prokinesia. Gastroenterology 1994; 106: 1112-4.